These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
147 related articles for article (PubMed ID: 9210602)
41. Antibody responses to the hepatitis C virus E2 protein: relationship to viraemia and prevalence in anti-HCV seronegative subjects. Cerino A; Bissolati M; Cividini A; Nicosia A; Esumi M; Hayashi N; Mizuno K; Slobbe R; Oudshoorn P; Silini E; Asti M; Mondelli MU J Med Virol; 1997 Jan; 51(1):1-5. PubMed ID: 8986942 [TBL] [Abstract][Full Text] [Related]
42. Glycylglycine promotes the solubility and antigenic utility of recombinant HCV structural proteins in a point-of-care immunoassay for detection of active viremia. Shawky H; Tabll AA; Elshenawy RM; Helmy NM; Moustafa RI; Elesnawy YK; Abdelghany MM; El-Abd YS Microb Cell Fact; 2024 Jan; 23(1):25. PubMed ID: 38238770 [TBL] [Abstract][Full Text] [Related]
43. [Expression of hepatitis C virus genome]. Nishihara T; Mizuno K; Shikata T Nihon Rinsho; 1993 Feb; 51(2):323-8. PubMed ID: 7681882 [TBL] [Abstract][Full Text] [Related]
44. Evaluating replication-defective vesicular stomatitis virus as a vaccine vehicle. Majid AM; Ezelle H; Shah S; Barber GN J Virol; 2006 Jul; 80(14):6993-7008. PubMed ID: 16809305 [TBL] [Abstract][Full Text] [Related]
45. Chimeric hepatitis B virus/hepatitis C virus envelope proteins elicit broadly neutralizing antibodies and constitute a potential bivalent prophylactic vaccine. Beaumont E; Patient R; Hourioux C; Dimier-Poisson I; Roingeard P Hepatology; 2013 Apr; 57(4):1303-13. PubMed ID: 23150224 [TBL] [Abstract][Full Text] [Related]
46. Incorporation of apolipoprotein E into HBV-HCV subviral envelope particles to improve the hepatitis vaccine strategy. Gomez-Escobar E; Burlaud-Gaillard J; Visdeloup C; Ribeiro E Silva A; Coutant P; Roingeard P; Beaumont E Sci Rep; 2021 Nov; 11(1):21856. PubMed ID: 34750487 [TBL] [Abstract][Full Text] [Related]
47. Characterization of hepatitis C virus structural proteins with a recombinant baculovirus expression system. Hsu HH; Donets M; Greenberg HB; Feinstone SM Hepatology; 1993 May; 17(5):763-71. PubMed ID: 8387945 [TBL] [Abstract][Full Text] [Related]
49. Usefulness of the hepatitis C virus core antigen assay for screening of a population undergoing routine medical checkup. Gaudy C; Thevenas C; Tichet J; Mariotte N; Goudeau A; Dubois F J Clin Microbiol; 2005 Apr; 43(4):1722-6. PubMed ID: 15814991 [TBL] [Abstract][Full Text] [Related]
50. Antibody response to core, envelope and nonstructural hepatitis C virus antigens: comparison of immunocompetent and immunosuppressed patients. Lok AS; Chien D; Choo QL; Chan TM; Chiu EK; Cheng IK; Houghton M; Kuo G Hepatology; 1993 Sep; 18(3):497-502. PubMed ID: 7689528 [TBL] [Abstract][Full Text] [Related]
51. Peptide immunogen mimicry of putative E1 glycoprotein-specific epitopes in hepatitis C virus. Ray R; Khanna A; Lagging LM; Meyer K; Choo QL; Ralston R; Houghton M; Becherer PR J Virol; 1994 Jul; 68(7):4420-6. PubMed ID: 8207814 [TBL] [Abstract][Full Text] [Related]
52. Characterization of secreted and intracellular forms of a truncated hepatitis C virus E2 protein expressed by a recombinant herpes simplex virus. Lucas M; Tsitoura E; Montoya M; Laliotou B; Aslanoglou E; Kouvatsis V; Entwisle C; Miller J; Klenerman P; Hadziyannis A; Hadziyannis S; Borrow P; Mavromara P J Gen Virol; 2003 Mar; 84(Pt 3):545-554. PubMed ID: 12604804 [TBL] [Abstract][Full Text] [Related]
53. Antibodies directed to envelope proteins of hepatitis C virus outside of hypervariable region 1. Lechner S; Rispeter K; Meisel H; Kraas W; Jung G; Roggendorf M; Zibert A Virology; 1998 Apr; 243(2):313-21. PubMed ID: 9568031 [TBL] [Abstract][Full Text] [Related]
54. Level of Human Antibodies Targeting HCV E1/E2 Peptides and Spontaneous Clearance of HCV in Blood Donors. Tabll AA; Salem EA; El-Abd YS; El-Shenawy RM; Saad A; Abdallah SO; Dawood RM; El-Awady MK Clin Lab; 2016 Oct; 62(10):1879-1885. PubMed ID: 28164540 [TBL] [Abstract][Full Text] [Related]
55. Serum antibodies against the hepatitis C virus E2 protein mediate antibody-dependent cellular cytotoxicity (ADCC). Nattermann J; Schneiders AM; Leifeld L; Langhans B; Schulz M; Inchauspé G; Matz B; Brackmann HH; Houghton M; Sauerbruch T; Spengler U J Hepatol; 2005 Apr; 42(4):499-504. PubMed ID: 15763336 [TBL] [Abstract][Full Text] [Related]
56. Native Folding of a Recombinant gpE1/gpE2 Heterodimer Vaccine Antigen from a Precursor Protein Fused with Fc IgG. Logan M; Law J; Wong JAJ; Hockman D; Landi A; Chen C; Crawford K; Kundu J; Baldwin L; Johnson J; Dahiya A; LaChance G; Marcotrigiano J; Law M; Foung S; Tyrrell L; Houghton M J Virol; 2017 Jan; 91(1):. PubMed ID: 27795422 [TBL] [Abstract][Full Text] [Related]
57. Detection by western blotting of an antibody to the hepatitis C virus E1 envelope protein in sera of patients with chronic liver disease. Hada H; Koide N; Hanafusa T; Sakaguchi K; Shinji T; Sasaki S; Oka T; Takayama N; Yumoto Y; Tsuji T Acta Med Okayama; 1992 Oct; 46(5):365-70. PubMed ID: 1279946 [TBL] [Abstract][Full Text] [Related]
58. Expression, purification and immunogenic characterization of hepatitis C virus recombinant E1E2 protein expressed by Pichia pastoris yeast. Cai W; Su L; Liao Q; Ye L; Wu Y; Wu Z; She Y Antiviral Res; 2010 Oct; 88(1):80-5. PubMed ID: 20691736 [TBL] [Abstract][Full Text] [Related]
59. Induction of antibodies against structural proteins of hepatitis C virus in mice using recombinant adenovirus. Makimura M; Miyake S; Akino N; Takamori K; Matsuura Y; Miyamura T; Saito I Vaccine; 1996 Jan; 14(1):28-36. PubMed ID: 8821646 [TBL] [Abstract][Full Text] [Related]
60. Modulation of epitope-specific anti-hepatitis C virus E2 (anti-HCV/E2) antibodies by anti-viral treatment. Mancini N; Carletti S; Perotti M; Romanò L; Craxì RD; Craxì A; Zanetti AR; Clementi M; Burioni R J Med Virol; 2006 Oct; 78(10):1304-11. PubMed ID: 16927283 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]